Magnus Financial Group LLC Buys 333 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Magnus Financial Group LLC raised its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 12.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,917 shares of the biotechnology company's stock after purchasing an additional 333 shares during the period. Magnus Financial Group LLC's holdings in Axon Enterprise were worth $1,534,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC bought a new stake in shares of Axon Enterprise in the fourth quarter worth about $480,000. Caprock Group LLC purchased a new position in Axon Enterprise in the 4th quarter worth approximately $329,000. DAVENPORT & Co LLC raised its stake in Axon Enterprise by 7.6% during the 4th quarter. DAVENPORT & Co LLC now owns 894 shares of the biotechnology company's stock valued at $531,000 after buying an additional 63 shares during the last quarter. Mather Group LLC. raised its stake in Axon Enterprise by 3.6% during the 4th quarter. Mather Group LLC. now owns 786 shares of the biotechnology company's stock valued at $467,000 after buying an additional 27 shares during the last quarter. Finally, Sargent Investment Group LLC purchased a new stake in Axon Enterprise during the 4th quarter valued at $300,000. Hedge funds and other institutional investors own 79.08% of the company's stock.

Axon Enterprise Trading Up 1.1%

Shares of Axon Enterprise stock opened at $788.36 on Friday. The company has a market capitalization of $61.37 billion, a P/E ratio of 203.71, a P/E/G ratio of 5.17 and a beta of 1.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The company has a fifty day moving average of $638.88 and a 200 day moving average of $615.19. Axon Enterprise, Inc. has a fifty-two week low of $276.92 and a fifty-two week high of $793.24.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.34 by $0.07. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The business had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. During the same quarter in the prior year, the firm earned $1.15 EPS. The business's revenue was up 31.3% on a year-over-year basis. On average, sell-side analysts anticipate that Axon Enterprise, Inc. will post 5.8 earnings per share for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In related news, Director Jeri Williams sold 307 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $552.72, for a total value of $169,685.04. Following the completion of the transaction, the director now owns 1,627 shares of the company's stock, valued at approximately $899,275.44. This trade represents a 15.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Joshua Isner sold 9,000 shares of the stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $683.31, for a total transaction of $6,149,790.00. Following the completion of the transaction, the president now directly owns 308,714 shares of the company's stock, valued at approximately $210,947,363.34. The trade was a 2.83% decrease in their position. The disclosure for this sale can be found here. Insiders sold 43,969 shares of company stock valued at $29,909,594 in the last 90 days. Insiders own 4.40% of the company's stock.

Wall Street Analysts Forecast Growth

AXON has been the subject of several analyst reports. Northcoast Research lowered Axon Enterprise from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 19th. Craig Hallum lowered Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. The Goldman Sachs Group upped their price objective on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Barclays upped their price objective on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Finally, Bank of America upped their price objective on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $699.55.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.